[REVISION HISTORY]

Advancements in prostate cancer diagnostic imaging

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-25 12:47 UTC → 2026-10-08 02:27 UTC · added ~~removed~~

Medical research indicates that advancements in imaging technology, specifically the combination of PET/MRI with MRI-based scoring, show potential to improve prostate cancer detection. This combined approach has demonstrated an 87% accuracy rate in identifying clinically significant cancer, which outperforms using MRI or PET imaging individually. By utilizing these advanced imaging techniques, researchers suggest that up to 57% of patients might avoid unnecessary invasive biopsies, thereby reducing risks such as bleeding, infection, and pain. In the United States, while the use of MRI prior to a first prostate biopsy has risen from 14% in 2017 to 64% in early 2026, a gap in care persists. Approximately one-third of men still undergo biopsies without prior scans, a disparity attributed to challenges regarding insurance coverage and access. Recent findings published in the Journal of Nuclear Medicine further highlight the efficacy of combining MRI results with PSMA PET/CT-guided biopsies. In a study of 63 men, systematic biopsies alone detected cancer in 21% of cases where MRI findings were negative or inconclusive. However, PET/CT-guided biopsies achieved a 37% detection rate, and combining both approaches raised the overall detection rate to 41%. This combined method nearly doubles the effectiveness of systematic sampling alone and addresses a diagnostic gap where 20–30% of clinically significant cancers may be missed due to inconclusive MRI scans.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.